U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H28N4O2
Molecular Weight 272.387
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of EXAMETAZIME

SMILES

C[C@@H](NCC(C)(C)CN[C@H](C)C(\C)=N\O)C(\C)=N\O

InChI

InChIKey=BPNZYADGDZPRTK-UDUYQYQQSA-N
InChI=1S/C13H28N4O2/c1-9(11(3)16-18)14-7-13(5,6)8-15-10(2)12(4)17-19/h9-10,14-15,18-19H,7-8H2,1-6H3/b16-11+,17-12+/t9-,10-/m1/s1

HIDE SMILES / InChI
Technetium (99mTc) exametazime is a radiopharmaceutical agent, which is known as trade name Ceretec. The Ceretec kit is supplied as five packs of three vials for use in the preparation of a technetium Tc99m exametazime intravenous injection as a diagnostic radiopharmaceutical. When technetium Tc99m pertechnetate is added to exametazime in the presence of stannous reductant, a lipophilic technetium Tc99m complex is formed. This lipophilic complex is the active moiety. It converts at approximately 12%/hour to less lipophilic species. When the secondary complex is separated from the lipophilic species, it is unable to cross the blood-brain-barrier. The useful life of the reconstituted agent is limited to 30 minutes. This complex is used as an adjunct in the detection of altered regional cerebral perfusion in stroke. And in addition, is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. Also exist clinical trials, where this complex is used for diagnostic purposes in Crohn's Disease and in vascular prosthesis infection.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
CERETEC

Approved Use

Technetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.

Launch Date

5.9944318E11
Diagnostic
Unknown

Approved Use

Unknown
Diagnostic
CERETEC

Approved Use

Technetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.

Launch Date

5.9944318E11
Diagnostic
CERETEC

Approved Use

Technetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.

Launch Date

5.9944318E11
Diagnostic
CERETEC

Approved Use

Technetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.

Launch Date

5.9944318E11
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

The normal adult (70 kg) dose is 0.259-0.925 GBq (7-25 mCi) as Tc99m labeled leukocytes by intravenous injection. Optimal planar imaging is between 2-4 hours. Do not use methylene blue in the preparation of the Tc99m labeled leukocytes. Cerebral Scintigraphy: The recommended dose range for i.v. administration, of reconstituted sodium pertechnetate Tc99m exametazime (with or without methylene blue) in the average adult (70 kg) is 370-740 MBq (10-20 mCi). Dynamic imaging may be performed between 0 to 10 minutes following injection. Static imaging may be performed from 15 minutes up to 6 hours after injection.
Route of Administration: Intravenous
Whole blood (480 mL) was obtained from each of 3 healthy donors and divided equally into eight 60-mL aliquots. Two aliquots from each of the 3 subjects were used as a control (i.e., leukocytes were not labeled with either nonstabilized or stabilized 99mTc-exametazime) in this study. The remaining 6 aliquots from each of the 3 subjects were divided equally into the following formulation groups: (a) leukocytes labeled with nonstabilized 99mTc-exametazime, (b) leukocytes labeled with stabilized 99mTc-exametazime containing 250 microg methylene blue, and (c) leukocytes labeled with stabilized 99mTc-exametazime containing 500 microg methylene blue. It was revealed that, the methylene blue/phosphate buffer stabilizer (250 or 500 microg methylene blue) did not affect the cell membrane integrity, chemotactic capacity, labeling efficiency, in vitro stability, or complete blood count of leukocytes labeled with stabilized 99mTc-exametazime.
Name Type Language
EXAMETAZIME
II   INN   JAN   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
DL-HM-PAO
Code English
EXAMETAZIME [JAN]
Common Name English
Exametazime [WHO-DD]
Common Name English
DL HM-PAO
Code English
exametazime [INN]
Common Name English
DL-HEXAMETHYLPROPYLENE AMINE OXIDE
Common Name English
(±)-(3RS,3'RS)-3,3'-((2,2-DIMETHYLTRIMETHYLENE)DIIMINO)DI-2-BUTANONE (E,E)-DIOXIME
Common Name English
EXAMETAZIME [MI]
Common Name English
EXAMETAZIME [II]
Common Name English
2-BUTANONE, 3,3'-((2,2-DIMETHYL-1,3-PROPANEDIYL)DIIMINO)BIS-, DIOXIME, (R*,R*-(E,E))-(±)-
Common Name English
EXAMETAZIME [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1937
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
Code System Code Type Description
MERCK INDEX
m5223
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID1057614
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY
CAS
105613-48-7
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY
DAILYMED
G29272NCKL
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY
SMS_ID
100000082322
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY
PUBCHEM
9552071
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY
EVMPD
SUB07355MIG
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY
USAN
Z-40
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY
DRUG BANK
DB11179
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY
ChEMBL
CHEMBL2218892
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY
RXCUI
62153
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY RxNorm
FDA UNII
G29272NCKL
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY
NCI_THESAURUS
C65608
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY
INN
6094
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY
MESH
C078058
Created by admin on Sat Dec 16 17:51:06 UTC 2023 , Edited by admin on Sat Dec 16 17:51:06 UTC 2023
PRIMARY